ADVM Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of --. Adverum Biotechnologies's return on equity of -69.14% beat Nanoviricides's return on equity of --.

Adverum Biotechnologies has a consensus price target of $26.00, signalling upside risk potential of 756.09%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 407.81%. Given that Adverum Biotechnologies has higher upside potential than Nanoviricides, analysts believe Adverum Biotechnologies is more attractive than Nanoviricides.

Adverum Biotechnologies has a beta of 1.032, which suggesting that the stock is 3.196% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Adverum Biotechnologies quarterly revenues are $1M, which are larger than Nanoviricides quarterly revenues of --. Adverum Biotechnologies's net income of -$27.1M is lower than Nanoviricides's net income of -$2M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of --. Adverum Biotechnologies's return on equity of -69.14% beat Oragenics's return on equity of --.

Adverum Biotechnologies has a consensus price target of $26.00, signalling upside risk potential of 756.09%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 455.56%. Given that Adverum Biotechnologies has higher upside potential than Oragenics, analysts believe Adverum Biotechnologies is more attractive than Oragenics.

Adverum Biotechnologies has a beta of 1.032, which suggesting that the stock is 3.196% more volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Adverum Biotechnologies quarterly revenues are $1M, which are larger than Oragenics quarterly revenues of --. Adverum Biotechnologies's net income of -$27.1M is lower than Oragenics's net income of -$3.3M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus 1.12x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of --. Adverum Biotechnologies's return on equity of -69.14% beat Theriva Biologics's return on equity of --.

Adverum Biotechnologies has a consensus price target of $26.00, signalling upside risk potential of 756.09%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1252.66%. Given that Theriva Biologics has higher upside potential than Adverum Biotechnologies, analysts believe Theriva Biologics is more attractive than Adverum Biotechnologies.

Adverum Biotechnologies has a beta of 1.032, which suggesting that the stock is 3.196% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Adverum Biotechnologies quarterly revenues are $1M, which are larger than Theriva Biologics quarterly revenues of --. Adverum Biotechnologies's net income of -$27.1M is lower than Theriva Biologics's net income of -$4.4M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of -9.24%. Adverum Biotechnologies's return on equity of -69.14% beat Vanda Pharmaceuticals's return on equity of -3.49%.

Adverum Biotechnologies has a consensus price target of $26.00, signalling upside risk potential of 756.09%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 214.31%. Given that Adverum Biotechnologies has higher upside potential than Vanda Pharmaceuticals, analysts believe Adverum Biotechnologies is more attractive than Vanda Pharmaceuticals.

Adverum Biotechnologies has a beta of 1.032, which suggesting that the stock is 3.196% more volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.259%.

Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Adverum Biotechnologies quarterly revenues are $1M, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. Adverum Biotechnologies's net income of -$27.1M is lower than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus 1.18x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.